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ABSTRACT 
 
 
Regulation of Tumor Vascular Perfusion and Permeability by Endothelial Nck 
 
 
Gladys Pedraza 
Department of Biology 
Texas A&M University 
 
 
Research Advisor: Dr. Gonzalo Rivera  
Department of Veterinary Pathobiology  
Texas A&M University 
 
 
Tumor progression and metastasis is increased by the unique vasculature found in tumors 
which can be characterized as having low perfusion and increased permeability. The role of Nck 
proteins is to control actin cytoskeletal remodeling in response to signaling by tyrosine 
phosphorylation, which is important in developmental angiogenesis. The role of Nck in tumor 
angiogenesis still remains unknown. Our goal is to determine role of endothelial Nck in tumor 
angiogenesis and cancer progression. In order to do this, we used a syngeneic melanoma tumor 
model in combination with inducible, endothelial-specific deletion of Nck gene in mice. Tumor 
growth rate, tumor size at sacrifice were compared in both mice with and without endothelial 
Nck. Tumor growth rates and excised tumor size were found to be smaller in the knockout mice, 
which suggests that endothelial Nck facilitates tumor growth. This study aims to have an 
important positive impact on the subsequent development of new strategies to improve 
functionality in the tumor vasculature, and therefore, the efficacy of anticancer therapy.  
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CHAPTER I 
INTRODUCTION 
 
Importance of tumor vasculature in cancer progression and metastasis 
The function of tissues in our body is dependent on a mature and organized vascular 
network. Therefore, angiogenesis, the creation of new blood vessels, is critical for healthy human 
development (Goel, 2012).  In healthy tissue, angiogenesis is a highly regulated process (Dubrac, 
2016). It is typically induced in hypoxic tissues by the production of proangiogenic factors, such 
as vascular endothelial growth factor (VEGF), which is important for endothelial cell migration 
and survival. Angiogenesis is also dependent on microenvironmental influences like extracellular 
matrix, cell-cell interactions, and other soluble factors (Goel, 2012).  In addition, hypoxia which 
seems to be characteristic of the tumor microenvironment results in an increased production of 
proangiogenic factors (Semenza 2010). The abundance of these factors drives uncontrolled 
angiogenesis known as pathoangiogenesis as well as the production of a microvascular network 
with structural and functional abnormalities (Jain 2005; Goel, 2012).  These abnormalities 
further modify the microenvironment.  As a result both the abnormal vascular network and 
microenvironment of tumors lead to the progression of tumor growth and metastasis (Goel, 
2012).   
Current antiangiogenic therapies 
Antiangiogenic therapies, such as anti-VEGF therapy have been used to treat cancer. 
However, the results have failed to show significant response rates or prolongation of survival in 
cancer patients (Jain et al. 2006; Giantonio et al. 2007). In addition, anti-VEGF therapy has been 
used in conjunction with other anti-cancer treatments such as chemotherapy and have shown 
4 
 
better outcomes than either treatment alone (Goel, 2012).  While this combined approach has 
produced good initial outcomes, there is a lot of drawbacks. For one, these anti-angiogenic 
treatments have serious side effects which are hemorrhage and venous thromboembolism 
(Hapani, 2010; Nalluri, 2008) a meta-analysis; Risk of venous thromboembolism with the 
angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.) Secondly, the incidence 
of tumor metastasis increases with this approach  (Graeber, 1996). The benefits of anti-VEGF are 
short lived and are followed by tumor growth due to a response of adaptive resistance or 
preexisting non-responsiveness (Bergers, 2008). Therefore, there is the need for alternative 
targets to normalize tumor blood vessels in order to increase the effectiveness of anticancer 
therapies. 
Nck role in vascular biology   
The family of Nck adaptor proteins (Nck 1/α and Nck 2/β) are composed of three N-
terminal Src homology 3 (SH3) domains and one C-terminal SH2 domain and have overlapping 
noncatalytic functions (Chaki et al., 2015). Nck proteins link tyrosine phosphorylation with 
downstream effectors that regulate the cytoskeleton. These modular adaptors are required for the 
development of mesoderm-derived embryonic structures (Bladt et al., 2003) as well as EndMT 
and cardiovascular development (Clouthier et al., 2015). Our lab, among others, have shown that 
Nck plays an important role in cytoskeletal remodeling (Rivera et al., 2004; Rivera et al., 2009), 
breast cancer progression (Morris et al., 2017), and sprouting angiogenesis (Chaki et al., 2013; 
Chaki et al., 2015). 
Objective  
In this application the objective is to determine the role of endothelial Nck in tumor 
angiogenesis and cancer progression. Our central hypothesis is that endothelial Nck facilitates 
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tumor growth and metastasis by prompting the development of a structurally disorganized, leaky, 
and poorly perfused tumor vasculature. This hypothesis was formulated based on existing 
literature demonstrating that Nck plays a role in actin remodeling (Rivera et al., 2004; Rivera et 
al., 2009) and that this remodeling plays a role in the abnormal endothelial response that leads to 
pathological angiogenesis  and the destabilization of blood vessels (Weis and Cheresh, 2011; 
Chaki et al., 2015). The rationale for this research is that identification of endothelial Nck as a 
critical target to help normalize tumor vasculature will decrease tumor growth and metastasis and 
increase treatment efficacy.    
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CHAPTER II 
METHODS 
 
Animals 
We established a colony of NckECKO (Cdh5CreERT2; Nck1-/-; Nck2loxP/loxP) mice in 
C57BL/6J background by backcrossing (5 generations) mixed breeding founders (kindly 
provided by Anne Eichmann)47 with C57BL/6J mice obtained from the Jackson Laboratory. 
More information can be found in provided in Appendix I. This mouse line enables the 
inducible, Cre-mediated excision of Nck2 specifically in the endothelium. Nck appears to be 
dispensable for the quiescent/mature adult vasculature since mice with postnatal Nck deletion 
maintained normal weight and did not exhibit an overt phenotype. 
Table 1: Animal groups. Description of genotype, sex, and number of mice in each group. 
Group Genotype Female Male Total 
iEC-NcK(KO) Nck1-/-; Nck2f/f; Cre+ n=9 n=7 n=16 
Control Nck1-/-; Nck2f/f; Cre- n=6 n=6 n=12 
 
Tamoxifen treatment 
Eight week-old NckECKO mice received 5 intraperitoneal injections of tamoxifen 
(75mg/kg) dissolved in corn oil, every other day, in a time period of 10 days to induce Cre 
activity. A step by step description of the procedure is provided in Appendix II. 
Western blot 
Levels of Nck in the tumor endothelium (CD31-expressing cells) were determined by 
western blotting performed on extracts of endothelial cells isolated from lungs (ML, 2009) 
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Cell culture 
B16-F10 melanoma cells were removed from liquid nitrogen storage and plated in HG 
DMEM supplemented with 10% heat-inactivated FBS (Gemini Bio) and 1% pen/strep 
(Invitrogen) 6 days before tumor cell injection. Cells were passaged one to two days before 
injection (Tian et al., 2017). A step by step description of this procedure is provided in Appendix 
III. 
Tumors 
A subcutaneous syngeneic tumor model of B16-F10 melanoma cells, widely used in 
studies of tumor angiogenesis (Park et al., 2016; Steri et al., 2014; Tsai et al., 2011) was utilized. 
Three days after the last tamoxifen injection, mice were anesthetized with isoflurane for 
subcutaneous allograft injection of 2.5x10^5 cultured B16F10 cells in 100ul PBS on each flank 
(Park et al., 2016).  A step by step description of the procedure is provided in Appendix IV.  
Tumor growth 
Tumors were measured using a digimatic caliper daily starting on day 8 post allograft 
transplantation. Tumor volume was calculated using the following formula: (Long side x (short 
side 2) x .5 (; Tsai et al., 2011). 
Euthanasia & Necropsy 
Euthanasia was carried out by CO2 asphyxiation 18 days after tumor cell injection. 
Tumors were excised and measured using a digimatic caliper. In addition, the lungs, liver and 
spleen were excised in order to determine extent of metastasis (Tsai et al., 2011). A step by step 
description of the procedure is provided in Appendix V. Ex vivo tumors were divided in halves 
for cryopreservation and paraffin embedding for further pathological and immunohistochemical 
analyses. 
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Quantification of the tumor vasculature 
Due to restrictions imposed by the Covid-19 pandemic, determinations of tumor vascular 
density were halted. These experiments will be resumed in the near future and quantitative 
analysis of tumor vascularization will be performed as follows. Briefly, the vascular density in 
tumor sections will be determined by immunohistochemistry using an anti-CD31 antibody 
(Abcam, AB28364) to visualize the endothelium (Maione and Giraudo, 2015; Stockmann et al., 
2008) as well as H&E staining. A step by step description of the immunohistochemistry 
procedure that will be followed is provided in Appendix VI.  
Imaging of immunohistochemistry will be done using Zeiss LSM 780 NLO Multiphoton 
Microscope with laser lines of 488 and 543 nm as well as an objective of Plan-Apo 20X/0.8. 
Tumor vasculature will then be quantified using Image J, a Java application used to analyze 
images. In addition, the surface area of blood vessels will be quantified using the surface area 
covered by antiCD31and comparing it to that of the rest of the tumor cells (Maione and Giraudo, 
2015). 
Statistics 
Minitab and Excel were used to conduct statistical analysis. Normal distribution was 
confirmed by the Kolmogorov-Smirnov test. The Student's t test was used to evaluate differences 
between means. P<0.05 was considered statistically significant. A Grubbs outlier test on Minitab 
will also be performed. 
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CHAPTER III 
RESULTS 
 
Tumor growth in vivo 
 
Measurements that were taken in vivo were used to calculate the volumes of individual 
tumors. The sums of the volumes (right and left) were found per each mouse, and a mean for all 
of these measurements was taken. These daily mean values were plotted to show a continuous 
growth curve (Fig. 1). The results suggest that overall mice lacking endothelial Nck experience 
slower tumor growth compared to our control group, which had both Nck genes.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Growth curve. Average in vivio tumor volumes were plotted daily. The graph shows 
a decrease growth in Nck (KO) mice. 
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Tumor size ex vivo 
Once these mice were sacrificed, the measurements of the excised tumors were taken. 
Volumes of these measurements were calculated and the sums (right and left) were found per 
each mouse. These sums were then used to create a box plot (Fig. 2), which once again suggests 
that mice lacking endothelial Nck have decreased ex vivo tumor volume. In addition, statistical 
analysis showed that the difference between these two groups was statistically significant with a 
p value less than .05.  
Furthermore, these measurements were discriminated by sex. The boxplot (Fig. 3) 
showed that males and females seem to display differential tumor growth in response to 
endothelial Nck deletion.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Ex-vivo tumor volume box plot. Average ex-vivo tumor volumes were plotted. This 
plot shows the median of the control group being higher than the Nck (KO) group 
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Figure 3: Ex-vivo tumor volume by gender box plot. Average ex-vivo tumor volumes were 
plotted by sex. This plot shows the median of the male control group being higher than the 
median of the male Nck(KO) group. 
 
 
 
 
 
Figure 4: Pictures of extracted tumors. Each picture is a tumor that is representative of each 
group. 
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Western blot analysis 
In order to ensure that deletion of endothelial Nck took place, a western blot anlysis was 
used (Fig. 4). Expression levels of Ve-cadherin, an endothelial specific marker and Nck were 
tested in two conditions. The first condition applied was tamoxifen and the second was corn oil, 
a control condition. The decreased levels of Nck shown when tamoxifen was present in 
comparison to the normal levels shown in the control group, showed the effective deletion of 
Nck. In addition, the expression of Ve-cadherin in both conditions, showed that this gene is not 
being expressed specifically in the endothelium.  
 
 
 
 
 
 
 
 
Figure 5: Western blot analysis. Nck and VE-Cadherin markers were subjected to western blot 
analysis with tamoxifen being present in one group and corn oil in the control group. B-Actin 
served as a loading control. 
 
Quantification of the tumor vasculature 
Due to restrictions imposed by the Covid-19 pandemic, determinations of tumor vascular 
density were halted. These experiments will be resumed in the near future and quantitative 
analysis of tumor vascularization will be conducted using anti-CD31 antibody (Abcam, 
AB28364) to visualize the endothelium. Anti-CD31 was optimized Figure 6 shows the results of 
immunohistochemistry optimization of antiCD31 on tumor tissue. This antibody fluoresces red 
and allows for the visualization of the endothelium, which will allow the quantification of tumor 
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vascular density with Image J. In addition, H&E staining will also be conducted to measure the 
vascular density as shown in Figure 7.  
 
 
 
Figure 6: Immunohistochemistry. Optimization of anti-CD31, which allows for the 
visualization of the endothelium that lines blood vessels, as shown in red.  
 
 
 
 
 
 
 
 
 
 
Figure 7: H&E staining. Allows for the distinction of certain cell types like blood cells shown 
in dark pink, and therefore quantification of tumor vascular density. 
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CHAPTER IV 
CONCLUSION 
 
Preliminary data 
 
The growth curve of the in vivo tumors showed that overall mice lacking endothelial Nck 
experience slower tumor growth compared to the control group. Additionally, the box plots of 
the excised tumor volumes showed that mice lacking endothelial Nck have decreased ex vivo 
tumor volume. In conclusion, the preliminary data shows that deletion of endothelial Nck results 
in decreased tumor growth. 
Future direction  
Analysis of density of vasculature in tumors will be done using immunohistochemistry 
and H&E staining will be done. To ascertain functionality of tumor vasculature, vessel perfusion 
will be quantified by retroorbital injection of FITC-lectin (Maione and Giraudo, 2015). Tumor 
vascular permeability will be quantified using retroorbital injection of FITC-conjugated 40kDa 
dextran (Maione and Giraudo, 2015). Additional tumor models will also be implemented.  
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APPENDIX I 
TAMOXIFEN PREPARATION 
 
Tamoxifen Preparation Day 1:  
 
Materials: 
• Microcentrifuge tubes (VWR, cat# 89000-044) 
• Tamoxifen (Cayman Chemicals, cat#13258)  
• Corn oil 
*Tamoxifen is a potential carcinogen- be sure to wear appropriate PPE while handling: lab 
coat & mask* 
 
Procedure: 
1. Aliquot 100 uL filter-sterilized corn oil per mouse to be injected into a 1.5 mL 
microcentrifuge tube. Note: Prepare an extra dose for every 3 mice. 
2. Weigh 2 mg of tamoxifen per mouse to be injected and add to corn oil 
3. Briefly vortex until tamoxifen is distributed equally throughout solution 
4. Wrap microcentrifuge tube in aluminum foil (tamoxifen is light sensitive) 
5. Incubate tamoxifen solution with shaking at 37°C overnight 
 
 
Tamoxifen Preparation Day 2: 
 
Materials:  
Insulin syringes (True plus 29 gauge .3cc ½” insulin needles, cat#56151-1711-01) 
 
Procedure: 
1. Remove tamoxifen from the incubator shaker, and examine it in order to verify that it is 
fully dissolved. If not fully dissolved, place in a hot plate at 55°C and vortex every 5-10 
minutes, until fully dissolved 
2. Once tamoxifen is fully dissolved, pipette 130 uL of solution into an insulin syringe. 
Note: 100uL doses are required; extra is used to account for pipetting error 
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APPENDIX II 
CELL CULTURING 
 
Day One: Thawing and plating frozen cells  
 
Materials: 
• 10cm tissue culture dishes 
• Complete media (High glucose DMEM with 10% FBS and 1% v/v penicillin 
streptomycin) 
• DPBS  
• DMEM 
• Trypsin/EDTA (.05mg/mL)  
• 50 mL tube 
• Hemocytometer 
 
Procedure: 
1. One week before implantation, remove approximately one-third the necessary amount of 
cells from liquid nitrogen (ex: 2 mice require 1x106 cells, so remove 30x104 cells) 
2. Thaw cells in 37°C water bath and resuspend in complete media 
3. Aliquot 30x104 cells and plate in 10 mL media on 10 cm culture dishes 
4. After plating, incubate cells at 37°C in 5% CO2 
5. Change media the next day and every other day from then until culture is 40-50% 
confluent 
6. Passage cells once 50% confluent. Do this 1-2 days before injection to make sure that 
cells are in their logarithmic growth phase 
 
Day when cells 50% confluent: Passaging of cells  
 
1. Warm complete media, DPBS and DMEM at room temperature   
2. Aspirate all media  
3. Wash culture dishes twice using 3-5 mL of DPBS 
4. Add 0.75mL of Trypsin/EDTA dropwise to each dish 
5. Incubate dishes at 37°C for four minutes, and tap on the plates every two minutes to 
facilitate cell detachment 
6. Checked dishes under the microscope for cell adhesion 
7. Add 3 mL complete media to neutralize Trypsin activity 
8. Transfer cells to 15 mL tube and wash dishes with 3-5 mL unsupplemented DMEM to 
collect residual cells  
9. Centrifuge cells at 800 RPM for 5 minutes 
10. Aspirate supernatant   
11. Add and mix 10 mL fresh complete media  
20 
 
12. Count cells using a hemocytometer. Plate 30x104 cells in 10 mL complete media on new 
10 cm culture dishes 
13. Rock dishes gently to ensure even cell distribution and incubate at 37°C 
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APPENDIX III 
TUMOR CELL INJECTIONS 
 
Preparing Cells for Injection 
 
Materials: 
• Complete media (high glucose DMEM with 10% FBS and 1% P/S) 
• DPBS 
• Trypsin EDTA 
• 1.5 mL microcentrifuge tubes 
 
Procedure: 
1. Aspirate media 1-2 hours before injection, and wash culture dishes twice using 3-5mL of 
DPBS at room temperature 
2. Add 0.75 mL Trypsin/EDTA dropwise to dishes and incubate at 37°C for about 4 
minutes 
3. Check dishes under the microscope for cell adhesion 
4. Use 1mL of complete media to neutralize trypsin activity 
5. Collect cells in 15 mL centrifuge tubes and wash dishes with 3-5 mL DPBS to collect 
residual cells  
6. Centrifuge cells for 5 minutes at 800 RPM 
7. Aspirate supernatant  
8. Resuspend cells in 1 mL DPBS per plate 
9. Count cells using a hemocytometer and calculate viability using Trypan blue. Do not use 
cultures with less than 90% viability 
10. Calculate the volume of DPBS needed to achieve 2.5x10^5 cells per 100 uL and adjust 
for it 
11. Place cells on ice  
12. Aliquot 200 uL for each mouse in a 1.5mL microcentrifuge. Keep and transport on ice 
packs  
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Injection 
 
Materials: 
• Isoflurane anesthesia cart  
• Depilatory 
• Cotton swabs 
• Kimwipes 
• Beaker of water 
• Cell suspension  
• Mice  
• Insulin syringes 
 
Procedure:  
1. Weigh mouse 
2. Anesthetize animals using 2L/min isoflurane 
3. Apply depilatory cream to both flanks above hind limb 
4. Continuously rub cotton swabs on the application area until depilation begins 
5. Remove excess cream using wet cotton swabs and kimwipes to prevent chemical burns 
6. Take out cell suspension from cooler and resuspended  
7. Draw 125 uL into insulin syringe 
8. Tent skin above hind limb for insertion of needle, bevel down, and slow injection of cell 
suspension 
9. Remove needle 5 seconds after successful bleb formation to minimize leaking 
10. Repeat the same process on the opposite side flank 
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APPENDIX IV 
EUTHANASIA & NECROPSY 
 
Materials:  
• 1mL syringes 
• 26G ¾ in needles 
• Dissecting scissors and forceps 
• 10% NBF 
• Caliper 
• 10mM EDTA in DPBS 
 
Procedure: 
1. Euthanize mice by CO2 asphyxiation  
2. Spray body with isopropyl 
3. Perform exsanguination via cardiac puncture 
4. Lift and cut skin transversely using dissecting scissors 
5. Use small iris scissors to cut through abdominal wall 
6. Cut femoral artery  
7. Cut diaphragm through and pull back rib cage to expose the heart  
8. Perfuse 3-5 mL PBS/EDTA at the apex of the heart at a rate of 1mL/min. Judge perfusion 
on paleness of liver 
9. Perfuse 2mL 10% NBF through the apex of the heart 
10. Carefully excise and weigh tumor w 
11. Measure excised tumors (LxWxH) with digital caliper and store in 10% NBF at 4°C 
overnight 
12. Excise lungs, liver and spleen and store in 10% NBF at 4°C 
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APPENDIX V 
IMMUNOHISTOCHEMISTRY  
 
Day 1:  
 
Fxation (for frozen tissue samples only) 
 
Materials:  
Precooled acetone to about -20C 
 
Procedure: 
• Immerse slides in precooled acetone for 10 minutes  
• Let slides dry at room temperature for 10 minutes  
 
 
Rehydration  ( Steps 1-3 for paraffin embedded tissue samples only) 
 
Materials:  
• EtOH:100%, 95%, 80%, & 70% 
• H2O 
• Xylene 
Procedure:  
1. Wash slides twice in Xylene for 3 minutes  
2. Wash slides twice in 100% EtOH for 3 minutes  
3. Wash slides for 3 minutes each in 95%, 80%, & 70% EtOH.  
4. Wash slides twice in H2O for 5 minutes  
 
 
Antigen Retrieval (For paraffin embedded tissue samples only) 
 
Materials: 
• 10 mM sodium citrate 
• Tween 20  
• dH2O 
• Microwave 
 
Procedure:  
1. Note: Prepare antigen retrieval buffer before beginning IHC: 
2. Mix 2.94g of sodium citrate with approximately 1000mL of dH2O and bring to pH of 6 
using HCl 
3. Add 500uL of Tween 20 to the solution and it vortex until dissolved 
4. Immerse slides with more than enough antigen retrieval buffer 
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5. Place immersed slides in the microwave for 4 minutes and take out to cool for 2 minutes. 
Repeat this 5 times 
6. Leave slides to cool for 20 minutes 
7. Wash slides 3 times in dH2O for 5 minutes 
 
Blocking  
 
Materials:  
• Bovine Serum Albumin (BSA) 
• PBS 
• 10 mL syringe  
• Syringe filter 
 
Procedure: 
1. Note: Make 5% BSA before IHC was started:  
2. Add .5g of BSA to 10mL of PBS  
3. Vortex solution for a couple of seconds, then leave sitting for 10 minutes 
4. Filter solution  
5. Add 200 uL of blocking solution (5% BSA) to each tissue and incubate at room 
temperature for 30 minutes 
6. Dip slides in PBS briefly 
 
Primary Antibody 
 
Materials: 
• Bovine Serum Albumin (BSA) 
• PBS 
• 10 mL syringe  
• Syringe filter 
• Primary antibodies:  
• Anti-CD31 (Ab28364) 
• Normal Rabbit Immunoglobulin G 
• Isolectin B4 
• 15 cm plates 
• Filter paper 
• Parafilm 
 
Procedure: 
1. Note: Prepare 1% BSA before starting IHC : 
a. Add 1g of BSA to 10mL of PBS  
b. Vortex solution for a couple of seconds then leave sitting for 10 minutes 
c. Filter solution  
2. Dilute antibodies in 1% BSA and make enough for 250 uL per tissue sample 
a. Anti-CD31 (Ab28364): 1:50 
b. Normal Rabbit Immunoglobulin G & Isolectin B4: 1:100 
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3. Create humidifier chambers:  
c. Place a rectangular piece of filter paper in a 15 cm plate and moisten using ddH2O 
d. Place a piece of squared parafilm (the same size as the filter paper) on top to 
protect the slides from the water.  
4. Place slides in the humidifier chambers  
5. Apply 200 uL of diluted primary antibody to each tissue sample on each slide.  
6. Incubate slides in humidifier chambers at 4°C overnight  
 
 
Day 2: Secondary Antibody 
 
Materials: 
• PBS 
• BSA 
• EtOH: 70%, 80%, 95%, and 100% 
• Xylene 
• Prolong diamond mounting media 
• Secondary antibody: AF546  
 
Procedure: 
a. Wash slides 3 times with PBS, while covered on a shaker, for 5 minutes 
b. Dilute secondary antibody AF546 (1:500) with 1% BSA and enough was made for 250 uL 
per sample 
c. Apply 200 uL of secondary antibody to each tissue sample  
d. Cover slides and incubate them at room temperature for 1 hour 
e. Wash slides 3 times with PBS, while covered on a shaker, for 5 minutes 
f. Dip slides 10 times into each solution of: 70%, 80%, and 95% EtOH 
g. Dip slides 20 times into solution of 100% EtOH and then into solution of Xylene 
h. Apply mounting media and coverslips to each tissue sample.  
 
 
 
